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A B S T R A C T
Amphetamine-related drugs, such as 3,4-methylenedioxymethamphetamine (MDMA) and metham-
phetamine (METH), are popular recreational psychostimulants. Several preclinical studies have
demonstrated that, besides having the potential for abuse, amphetamine-related drugs may also elicit
neurotoxic and neuroinﬂammatory effects. The neurotoxic potentials of MDMA and METH to
dopaminergic and serotonergic neurons have been clearly demonstrated in both rodents and non-
human primates. This review summarizes the species-speciﬁc cellular and molecular mechanisms
involved inMDMA andMETH-mediated neurotoxic and neuroinﬂammatory effects, along with themost
important behavioral changes elicited by these substances in experimental animals and humans.
Emphasis is placed on the neuropsychological and neurological consequences associated with the
neuronal damage. Moreover, we point out the gap in our knowledge and the need for developing
appropriate therapeutic strategies to manage the neurological problems associated with amphetamine-
related drug abuse.
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The primary brain targets for the damage induced by both 3,4-
methylenedioxymethamphetamine (MDMA) and methamphet-
amine (METH) are the striatum and the substantia nigra (SN). Thus,
dysregulation of nigro-striatal dopaminergic system is the major
cause of motor impairments induced by these drugs of abuse.
Moreover, inﬂammatory effects of MDMA and METH play a
signiﬁcant role in the eventual dopaminergic dysregulation and
symptom manifestation by these drugs. Hence, we will present a
short overview on dopamine (DA) transmission and receptors and
the role of neuroinﬂammation in neurodegenerative diseases with
particular focus on these two drugs.
MDMA and METH may act as indirect DA agonists, producing
their effects through DA receptors. These receptors are coupled to
heterotrimeric G proteins and are classiﬁed into two families: D1-
like (which includes D1 and D5 receptors in mammals) and D2-like
(which includes D2, D3 and D4 receptors) receptor families.
Initially, these two families were deﬁned functionally based on
their ability to modulate adenylyl cyclase (AC) activity and cAMP
accumulation in cells, but later this classiﬁcationwas conﬁrmed by
molecular cloning (Beaulieu and Gainetdinov, 2011). The D1-like
receptors are found exclusively post-synaptically and activate the
Gas/olf family of G proteins to stimulate AC and cAMP production.
The D2-like family are expressed both pre- and post-synaptically
and activate the Gai/olf family of G proteins to inhibit AC and cAMP
production (Beaulieu and Gainetdinov, 2011). There exist two
variants of D2 receptors: D2-short (D2-S) and D2-long (D2-L) (Giros
et al., 1989; Monsma et al., 1989). The D2-S variant is expressed
mostly pre-synaptically and is involved in autoreceptor functions
(e.g. control of DA release and regulation of extrasynaptic DA
levels), whereas D2-L is mainly a postsynaptic isoform (Usielloet al., 2000; De Mei et al., 2009). In addition, D2-S potentiates DA
transporter (DAT) activity via the formation of heteromeric
protein–protein complexes with DAT localized in the dopaminer-
gic terminals (Hadlock et al., 2010). Interestingly, the distribution
of DA receptors is similar in humans and rodents (Ares-Santos
et al., 2013).
The signiﬁcance of DA receptors is reﬂected in the diverse
action of DA in behavior and cognition, voluntary movement,
motivation, punishment and reward, attention, learning and
working memory (Granado et al., 2008a; Martı´n et al., 2008;
Darmopil et al., 2009; Darvas and Palmiter, 2009, 2010; Ortiz et al.,
2010; Murer and Moratalla, 2011; Espadas et al., 2012; Ruiz-
DeDiego et al., 2015a,b). Moreover, DA receptors (e.g. D1-like
receptors) may mediate the interactions between glutamatergic
and dopaminergic systems (Rodrigues et al., 2007). Consistentwith
this broad spectrum of activities, there is a wide expression of DA
receptors in the brain. Both D1-like and D2-like receptor subtypes
are present in all of the known DA projection ﬁelds in the CNS and
their expression generally overlaps in most brain areas. Moreover,
D1-like and D2-like receptors are highly expressed in the striatum,
nucleus accumbens, olfactory bulb, amygdala, frontal cortex and
SN and, at lower levels, in the hippocampus and ventral tegmental
area (VTA) (Moratalla et al., 1996a; Beaulieu and Gainetdinov,
2011; Gangarossa et al., 2012). The striatum, one of the areas most
affected by MDMA and METH, is the site with the highest
concentration of DA in the brain. Although multiple DA receptor
subtypes are present in the striatum, the D1-like and D2-like
receptors are the most abundant in this area. Interestingly, D1- and
D2-containing projection neurons are segregated in the striatum,
as well as in the nucleus accumbens (Callier et al., 2003; Beaulieu
and Gainetdinov, 2011; Sua´rez et al., 2014). D1 receptor is
selectively expressed in striatal projection neurons that form
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selectively expressed in the striatal projection neurons that form
the indirect projecting pathway to the SN by ﬁrst projecting to the
globus pallidus (Beaulieu and Gainetdinov, 2011; Sua´rez et al.,
2014).
Loss of neurons and neuroinﬂammation are two connected
responses in neurodegenerative diseases. Brain immunological
response to insults such as infection, injury, toxic agents, or stress,
is primarily mediated by the glia cells that remove or inactivate
potentially damaging agents or damaged tissue. However, over-
activation of this system, reﬂected in elevated levels of immuno-
logical markers such as pro-inﬂammatory cytokines, can result in
neuroinﬂammation, leading to changes in brain structure and
synaptic plasticity, and eventually neurodegeneration (Hayley
et al., 2005; Leonard, 2007; Patterson, 2014).
It is of importance to note that chronic stress may exacerbate
the release of pro-inﬂammatory cytokines such as tumor necrosis
factor (TNF)-a, interleukin (IL)-1b, and IL-6 that can precipitate, or
aggravate, neurological diseases like Alzheimer’s disease
(Wuwongse et al., 2010), amyotrophic lateral sclerosis, epilepsy,
Huntington’s disease, multiple sclerosis, and Parkinson’s disease
(PD) (Hemmerle et al., 2012). Thus, drugs that prevent or
counteract the detrimental consequences of stress on inﬂamma-
tory pathways may offer novel treatments for a variety of
neurodegenerative pathologies (Hurley and Tizabi, 2013).
As mentioned above, glial cells, particularly microglia, are the
primary modulators of inﬂammation in the CNS (Stoll and Jander,
1999; Block et al., 2007) as they constantly ‘‘survey’’ their
environment and utilize their constitutively expressed surface
receptors to trigger or amplify responses to a given insult (Aloisi,
2001). Glial activation can quickly lead to the release of both pro-
and anti-inﬂammatory cytokines, where the ﬁnal effect is
dependent on the balance between these opposing responses.
It is believed that a dysregulation, or breakdown, of the normal
response triggered by any of the stimuli mentioned above can
cause inﬂammation to become persistent and harmful (Gao and
Hong, 2008). For example, inﬂammation induced by lipopolysac-
charide (a compound derived from membrane of Gram-negative
bacteria causing inﬂammatory-mediated damage) can result in
long term increase in TNF-a from brain microglia months after it
has subsided in the periphery (Qin et al., 2007). This increased pro-
inﬂammatory response may result in a delayed and progressive
loss in dopaminergic neurons in the SN, similar to that seen in PD,
strengthening the suggestion that unregulated neuroinﬂammation
could lead to neurodegeneration (Qin et al., 2007).
2. 3,4-Methylenedioxymethamphetamine (MDMA; ‘‘ecstasy’’)
2.1. History of MDMA
MDMA, also known as ‘‘ecstasy’’, is a ring-substituted amphet-
amine that belongs to the phenylisopropylamine class of
substances, and has marked psychostimulant properties (Green
et al., 2003; Lyles and Cadet, 2003).
MDMA was ﬁrst synthesized and patented around 1912 by
Ko¨llisch at the German pharmaceutical companyMerck. It was not
tested pharmacologically at the time because it was only regarded
as being an intermediate in a new synthetic pathway for
hemostatic substances (Freudenmann et al., 2006). In 1953, a
large toxicological study was performed at the University of
Michigan, in the USA, where MDMA was administered to ﬁve
animal species. These results were published in 1973 by Hardman
and colleagues, and indicated, for the ﬁrst time, the half lethal dose
of MDMA in each species (Hardman et al., 1973). The next phase of
research on MDMA began with the studies and work by Alexander
Shulgin. According to his autobiography and interviews, in1977 Shulgin introduced MDMA to Leo Zeff, a retired psychologist
from Oakland (CA, USA), who was so impressed by the effects of
MDMA that he decided to come out of retirement, and began to
introduce MDMA to other psychotherapists across the USA
(Benzenho¨fer and Passie, 2010). The appeal of MDMA that has
led to its use in psychotherapy is chieﬂy due to the particular
proﬁle of action of this substance, which includes amphetamine-
like stimulant effects togetherwith feelings of increased emotional
sensitivity and closeness to other individuals (Kirkpatrick et al.,
2014). Similar to other amphetamine-related drugs, MDMA
induces a state of ‘‘high’’, mainly characterized by disinhibition
in social relations, openness of spirit, increased empathy toward
other people, increased self-esteem and self-conﬁdence, euphoria,
increased vigilance, improvement ofmood, and abolition of fatigue
(Downing, 1986; Greer and Tolbert, 1986; Kirkpatrick et al., 2014).
MDMA has been popular as a recreational drug since the mid
1980s, and is often consumed in dance clubs because of its effects
on mood and social relations (Hall and Henry, 2006).
2.2. General toxicity of MDMA
Although MDMA generally elicits ‘‘positive’’ effects, up to the
25% ofMDMAusers report having had at least one adverse reaction
to the substance (Davison and Parrott, 1997; Green et al., 2003;
Morton, 2005). Acute toxicity elicited by MDMA in humans and
experimental animals includes effects on the neuroendocrine and
thermoregulatory systems, in particular induction of hyperther-
mia, and on the cardiovascular system (Gordon et al., 1991;
Vollenweider et al., 1998; de la Torre et al., 2000). In this regard, it
is worth mentioning that the typical environmental conditions
featuring dance clubs, where music is deafening and room
temperatures are high due to crowding, together with the fact
that club-goers usually consume little water and considerable
amounts of ethanol, are crucial to amplifying MDMA-induced
hyperthermia (Green et al., 2003).
Hyperthermia is a major clinical problem associated with the
use of MDMA, and the issue of MDMA-induced hyperthermia is
complex, since the biological mechanisms involved in heat
production and progression to hyperthermia after exposure to
the drug are not clearly understood. It is feasible to hypothesize
that the increased release of monoamines following MDMA
administration may stimulate receptors involved in thermoregu-
lation (Shankaran andGudelsky, 1999). Thiswould suggest that DA
could also be involved in MDMA-induced hyperthermia (Green
et al., 2003). Moreover, MDMA may induce vascular constriction
by activating serotonin (5-HT) 5-HT1B and 5-HT2A receptors
(Gudelsky et al., 1986), thus interfering with the peripheral
thermoregulatory mechanisms of the body (Sprague et al., 2003).
MDMA affects neuroendocrine functioning by promoting the
release of 5-HT and noradrenaline (NA), in turn stimulating the
activity of the hypothalamus–pituitary–adrenal axis (HPA), and
increasing the levels of cortisol (de la Torre et al., 2000; Harris et al.,
2002; Farre´ et al., 2004). A recent article by Parrott and colleagues
(Parrott et al., 2014) has reviewed the results obtained in several
earlier studies (Parrott et al., 2001, 2007, 2008), and reported that
MDMA users experience an 800% increase in the salivary levels of
cortisol after clubbing, compared with pre-drug baseline. More-
over, the same review reported that heavyMDMAusers exhibited a
400% increase in hair cortisol levels 3 months after drug
discontinuation, compared with both light MDMA users and
non-users. In this regard, it is noteworthy that the HPA releases
cortisol to cope with stressful situations, and that cortisol
reactivity and homeostasis can be impaired when the body is
subjected to repeated stressors. This impairment is reﬂected by
deﬁcits in core psychological functions, including memory,
cognition, sleep, and well-being (Parrott et al., 2014). Therefore,
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as an acute metabolic stressor (Parrott, 2006; Parrott et al., 2014).
MDMA consumed for recreational purposes produces transient
and dose-dependent cardiovascular effects, such as tachycardia
and moderate increases in both systolic and diastolic blood
pressure (Vollenweider et al., 1998). It should also be mentioned
that MDMA may exacerbate latent cardiovascular problems, such
as labile hypertonia, and that high or repeated doses of MDMA,
such as those that are often consumed during all-night dance
sessions, may potentially lead to severe hypertensive reactions and
arrhythmias (Vollenweider et al., 1998). Remarkably, hyperten-
sion, in combination with coagulopathy, might be potentially
responsible for the cerebral insults induced by MDMA, as
suggested by a single case report (Vollenweider et al., 1998).
2.3. Neurotoxicity of MDMA
A number of reports have demonstrated thatMDMA binds to all
three presynaptic monoamine transporters, although interspecies
differences for this effect exist. In rats, MDMA has the highest
afﬁnity for the 5-HT transporter (SERT), and lower afﬁnities for the
NA transporter (NET) and DAT (Steele et al., 1987; Rudnick and
Wall, 1992). Similar afﬁnities were reported in mice, although in
this species MDMA seems to act as a dopaminergic neurotoxin,
rather than a serotonergic neurotoxin (Kindlundh-Ho¨gberg et al.,
2007). In humans, and at variance with that observed in rodents,
MDMA displays higher afﬁnity for NET, and lower, but similar,
afﬁnities for SERT and DAT (Verrico et al., 2007). However, the
ability to release intracellular monoamines is higher in SERT-
expressing cells than in either DAT- or NET-expressing cells, and
this may justify the toxic effects of MDMA on SERT density
observed in the human brain (Reneman et al., 2001a,b). Once
translocated to the cytoplasm, MDMA increases the extracellular
levels of 5-HT, DA, and NA in multiple brain regions (Gudelsky and
Yamamoto, 2008). MDMA causes the dissipation of the proton
gradient between the vesicles and the cytosol that is necessary for
the proper functioning of the vesicular monoamine transporter
(VMAT2), inhibiting VMAT2-mediated inﬂux and proper storage of
5-HT, DA, and NA in the neuronal terminal (Rudnick and Wall,
1992; Cozzi et al., 1999). This event is boosted by the blockade of
the reuptake by presynaptic terminals, and by the partial inhibition
of the monoamine oxidase type B enzymes (MAO-B), located in the
outer membrane of the mitochondria of serotonergic neurons
(Leonardi and Azmitia, 1994).Table 1
Experimental studies on neurotoxicity of MDMA.
Species Protocol of MDMA administrat
Primary neuronal cultures of cerebral cortex Concentration range 100–800m
feeding for the following 24 or
Human SH-SY5Y neuroblastoma cells Concentration range: 100, 200
Mice 20 or 30mg/kg i.p. 3, at 3h i
Mice 5mg/kg i.p. 4, at 2h interval
Mice 10mg/kg i.p. 2, at 4–6h inte
5th days of the week, accordin
Mice 20mg/kg i.p 4, at 2h interva
Rats 20mg/kg s.c. 2, at 8h interva
Rats 10mg/kg i.p. 2, at 4h interva
Rats 15mg/kg o.s. 3, at 1.5h inter
Rats 10mg/kg i.p. 2, at 4h interva
Rats 5mg/kg i.p. every 5 days, PND
Non-human primates 2.50mg/kg, 3.75mg/kg, or 5.00
Non-human primates 2.5 or 10mg/kg i.m. 2, for 4
Non-human primates 5mg/kg s.c. 2, for 4 days
Non-human primates 10mg/kg i.m. 2, for 4 days
Non-human primates 2.5mg/kg i.m. 2, at 12h inte
a higher dose of MDMA (5mg
intervals, for 4 daysMDMA has attracted the attention of several researchers since
besides having abuse potential it may also elicit neurotoxic effects.
The occurrence of neurotoxicity induced by MDMA has been
investigated in both humans and experimental animals, although
the issue appears to be complex. In fact the features of MDMA-
induced neurotoxic damage seem to vary, depending on the gender
and strain of animals, which may inﬂuence the response to
different dosing regimens and administration routes of MDMA
(Ricaurte et al., 1988b; Colado et al., 1995; Itzhak et al., 2003). The
basis for the interspecies variations in MDMA neurotoxicity is still
unknown, but it has been suggested that differences in MDMA
disposition and metabolism by cytochrome P450 enzymes (CYP)
may play a key role in these variations (Green et al., 2012).
2.4. In vitro studies: cell cultures
Several studies have explored the effects of MDMA in cell
cultures, primarily cortical neurons and human neuroblastoma-
derived SH-SY5Y cells (Table 1). Cortical neurons can be studied in
serum-free cultures and contain virtually no microglia and few
astroglial cells (less than 10%, in respect to the total population).
These features allow for the evaluation of the speciﬁc effects of
MDMA on neurodegeneration, and the exclusion of the inﬂuence of
neuroinﬂammatory mechanisms (Capela et al., 2006a,b).
Using this model, Capela and coworkers (2006a,b) have
established a relevant in vitro paradigm to study MDMA-induced
neurotoxicity, in which they were able to reproduce the apoptotic
cell death elicited by the drug in vivo. In that study, the cultures
were treated with either MDMA or its metabolites, and were
incubated at normal temperature (36.5 8C) or at hyperthermic
temperature (40 8C) for 24 h. The study revealed that MDMA-
induced neurotoxicity in cortical neurons is not only concentra-
tion- and time-dependent, but also aggravated by hyperthermic
conditions. Moreover, MDMA-induced neuronal death was found
to follow an apoptotic pattern, which is at least partially mediated
by the direct stimulation of the 5-HT2A receptor (Capela et al.,
2006b).
Human SH-SY5Y cells are a tumor-derived cell line that has
attracted the attention of scientists involved in the study of
neurological diseases affecting dopaminergic neurons (Presgraves
et al., 2004; Brown et al., 2006). When differentiated with retinoic
acid, these cells express the features of a dopaminergic phenotype,
making them a suitable tool for evaluating the effects induced
by neurotoxins on dopaminergic neurons and the mechanismsion Reference
M; single application without
48h
Capela et al. (2006a,b)
, 400 and 800mM, for 24 or 48h Ferreira et al. (2013)
ntervals Granado et al. (2008a,b)
s Fornai et al. (2004)
rvals, twice weekly on the 2nd and
g to a 9-week administration schedule
Costa et al. (2013, 2014)
ls Frau et al. (2013a,b)
ls, post-natal day (PND) 11–20 Crawford et al. (2006)
ls, PND 35–60 Shen et al. (2013)
vals Xie et al. (2006)
ls every 5 days, PND 35–60 Piper and Meyer (2004) and
Meyer et al. (2008)
35–60 Piper et al. (2004, 2005)
mg/kg s.c. 2, at 9h intervals, for 4 days Ricaurte et al. (1988a)
days Insel et al. (1989)
Hatzidimitriou et al. (1999)
Frederick et al. (1998)
rvals, for 4 days. Eighteen days after,
/kg i.m.) was administered 2, at 12h
Winsauer et al. (2002)
R. Moratalla et al. / Progress in Neurobiology 155 (2017) 149–170 153involved (Presgraves et al., 2004; Brown et al., 2006). A study from
Ferreira and colleagues has analyzed the neurotoxic effect of
MDMA and its catecholmetabolitesa-methyldopamine (a-MeDA)
and N-Me-a-MeDA on SH-SY5Y cells (Ferreira et al., 2013). This
investigation found that these two metabolites of MDMA are
neurotoxic in a concentration- and time-dependent manner,
similar to that previously observed for MDMA in cortical neurons
(Capela et al., 2006a). However, the same study also found that
MDMA by itself failed to induce a concentration- and time-
dependent cell death, and that the neurotoxic effects of MDMA
metabolites in SH-SY5Y cells appeared to be completely indepen-
dent of caspase, which is crucial for the activation of neuronal
apoptotic pathways. In particular, a-MeDA and N-Me-a-MeDA
promoted cell rupture, a characteristic feature of necrosis.
Additionally, these MDMA metabolites promoted a signiﬁcant
mitochondrial dysfunction, as early as 24 h after their application.
Finally, a recent study, has conﬁrmed that the toxicity induced by
the catecholmetabolites of MDMA is potentiated by hyperthermia,
in line with earlier evidence (Barbosa et al., 2014). Taken together,
these in vitro experiments have contributed to the elucidation of
the mechanistic interactions of MDMA and its metabolites with
cellular components.
2.5. In vivo studies in experimental animals
2.5.1. Mice
When administered to mice, MDMA decreases the concentra-
tions of DA, 3,4-dihydroxyphenylacetic acid (DOPAC), and homo-
vanillic acid (HVA) in several brain regions. Moreover, and most
importantly, MDMA produces long-term degeneration of dopa-
minergic nerve terminals (Brodkin et al., 1993; Colado et al., 2001;
Izco et al., 2010; Costa et al., 2013) and a decrease in tyrosine
hydroxylase (TH), the rate-limiting enzyme for DA synthesis, in the
striatum (Green et al., 2003; Costa et al., 2013). A study by Granado
and coworkers has provided signiﬁcant insight into the elucidation
of the effects of MDMA on the nigrostriatal system of mice
(Granado et al., 2008b). The study demonstrated that MDMA
induces a loss of TH and DAT ﬁbers in the striatum, but not the
nucleus accumbens, indicating that the dopaminergic neurotoxic-
ity of MDMA targets the nigrostriatal system, while sparing the
mesolimbic pathway (Fig. 1). Interestingly, the same group
observed thatMDMAadministration induces a signiﬁcant decrease
in TH-positive neurons in the SN pars compacta (SNc), further
supporting the toxic effect of MDMA on the nigrostriatal system,
[(Fig._1)TD$FIG]
Fig. 1.MDMA affects the nigrostriatal pathway but has no effect in the mesolimbic path
nucleus accumbens shell and core (AcbSh, AcbC) respectively of mice treated with saliand that MDMA does not reduce the synthesis of TH, but rather
damages dopaminergic terminals, with an effect that appearsmore
pronounced in the striosomal compartment than in the matrix
(Granado et al., 2008c). Taken together, these results are in line
with earlier evidence describing dopaminergic terminal loss in the
mouse striatum following MDMA administration (Fornai et al.,
2004). Furthermore, and most notably, a similar pattern of
striosomal damage has been observed following the administra-
tion of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)
(Iravani et al., 2005). Since MPTP is a toxin known to induce PD
in humans and experimental animals, this would account for
similarities between the effects of MDMA and those of a
dopaminergic neurotoxin.
Recent studies have provided further preclinical evidence that
early exposure to MDMA may render the dopaminergic neurons
more vulnerable to the detrimental effects of later neurotoxic
insults. The neuroinﬂammatory and neurotoxic effects elicited by
MPTP in both motor (SNc and striatum), and non-motor
(hippocampus and medial prefrontal cortex) brain areas have
been shown to be more marked in adult mice treated with MDMA
during adolescence, compared with mice never exposed to MDMA
(Costa et al., 2013, 2014). Furthermore, these neurochemical
changes were associated with cognitive deﬁcits, which were
demonstrated by reduced performance in the novel object
recognition task, a behavioral test used to evaluate non-spatial
short-term memory in rodents (Costa et al., 2014). By contrast,
oleoylethanolamide, an endocannabinoid that reduce L-DOPA-
induced dyskinesias (Gonzalez-Aparicio and Moratalla, 2014) also
reduces cognitive deﬁcits and TH-induced byMDMA (Plaza-Zabala
et al., 2012). Interestingly, these results are in line with earlier
evidence that demonstrates the existence of noxious interactions
between MDMA and other substances that act on the CNS such
as ethanol (Izco et al., 2010; Ros-Simo´ et al., 2012) or caffeine
(Khairnar et al., 2010). A recent study revealed that the
coadministration of DPCPX, an A1 receptor antagonist, ampliﬁes
the effects of MDMA on both microglial and astroglial activation
in the striatum, suggesting that the A1 receptor could be the
adenosine receptor subtype most involved in the exacerbation of
MDMA-induced gliosis by caffeine (Khairnar et al., 2014).
An important point to consider when discussing the effects of
MDMA on the mouse brain, is that the majority of studies on this
issue have employed racemic ()-MDMA. However, evidence exists
that the effects of MDMA are stereospeciﬁc, as indicated by the
ﬁnding that S(+)-MDMA induces motor activation more efﬁcientlyway. Photomicrographs of TH immunoreactivity in the caudate putamen (CPu) and
ne (Sal) or MDMA. Bar indicates: 500 mm.
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reported that S(+)-MDMA elevates body temperature, while R()-
MDMA does not (Fantegrossi et al., 2003). A recent study by Frau and
coworkers has speciﬁcally investigated the effects elicited by either
MDMA enantiomer on body temperature and neuroinﬂammation in
mice. The results obtained have shown that S(+)-MDMA stimulates
the activation of bothmicroglia and astroglia in the striatum,whereas
R()-MDMA has no signiﬁcant inﬂuence on glial activation (Frau
et al., 2013b). Moreover, the same study observed a positive
correlation between the neuroinﬂammatory effects and the elevation
in body temperature stimulated by S(+)-MDMA. This could suggest
that a link may exist between hyperthermia and glial activation
observed in response to MDMA (Frau et al., 2013b). See Table 1 for
a summary of the protocols of the studies described above.
2.5.2. Rats
Earlier studies in adult rats have reported that MDMA may
damage serotonergic axons, terminals and cell bodies in areas such
as the hippocampus, hypothalamus, striatum, and neocortex
(Commins et al., 1987; Scallet et al., 1988). These results were
later conﬁrmed by other investigations and extended to other
brain areas such as the thalamus, septum, and amygdala (Adori
et al., 2006; Kova´cs et al., 2007). Remarkably, the toxic effects of
MDMA on markers of serotonergic viability lasted for weeks,
months, or even years, after drug discontinuation (Battaglia et al.,
1987; Fischer et al., 1995; Crawford et al., 2006). In addition to this,
it has been shown that astrocyte hypertrophy, leading to enhanced
expression of glial ﬁbrillary acidic protein (GFAP), can parallel the
damage to serotonergic ﬁbers observed after single MDMA
injection (Adori et al., 2006). Xie and coworkers studied the in
vivo expression of SERT after acute MDMA administration, and
compared the effects of MDMA with those of 5,7-dihydroxytryp-
tamine (5,7-DHT), a well-known serotonergic neurotoxin (Xie
et al., 2006). Interestingly, this investigation observed that MDMA
produced lasting reductions in 5-HT (5-hydroxyindoleacetic acid)
5-HIAA, and [3 [2_TD$DIFF]H]paroxetine-labeled SERT, similar to that observed
after the administration of 5,7-DHT, further indicating the ability of
MDMA to act as a serotonergic neurotoxin. However, it is
noteworthy that studies that examined the effects of prenatal or
neonatal exposure of rats to doses of MDMA known to be
neurotoxic in adult animals, have demonstrated that these MDMA
regimens produce little serotonergic neurotoxicity (Meyer et al.,
2004; Crawford et al., 2006).
The serotonergic system is implicated in sensation seeking,
inhibitory control, impulsivity, anxiety, regulation of mood, and
aggression (Linnoila et al., 1983; Jacobs and Fornal, 1999;
Winstanley et al., 2004). Furthermore, reduced serotonergic
activity is associated with heightened impulsivity and enhanced
sensation seeking (Linnoila et al., 1983), and lesions of the
serotonergic neurons elicit anxiolytic effects and increased
impulsivity in rats (Harrison et al., 1997; Soderpalm and Svensson,
1999). However, studies on the effects of MDMA-exposure in
experimental models of anxiety have produced conﬂicting data
(Morley and McGregor, 2000; Piper, 2007). With regard to the
long-standing controversy on the role of 5-HT in the regulation of
behavior in animal models of anxiety, Green and McGregor have
suggested that MDMA-induced 5-HT depletion might produce
either anxiolytic effects in rats with a high basal level of anxiety, or
anxiogenic effects in rats with a low basal level of anxiety (Green
and McGregor, 2002; Winstanley et al., 2004). However, a recent
study by Cox and coworkers has refuted this speculation, by
showing an anxiety-like behavior following repeated administra-
tion of MDMA and/or abstinence from MDMA (Cox et al., 2014).
Besides these emotional effects, MDMA has been reported to
induce learning deﬁcits (Piper and Meyer, 2004) and periadoles-
cent MDMA exposure has been found to be associated with abehavioral pattern reminiscent of impaired working memory and
behavioral disinhibition (Piper et al., 2005). At the same time,
Meyer and coworkers observed that periadolescent exposure
to MDMA is associated with a signiﬁcant reduction of SERT-
immunoreactive ﬁber density in the hippocampus (Meyer et al.,
2008). See Table 1 for a summary of the protocols of the studies
described above.
2.5.3. Non-human primates
Non-human primates appear to be very susceptible to the
neurotoxic effects of MDMA. A dose-dependent reduction in the
content of 5-HT in several brain regions has been observed in
squirrel monkeys after the repeated administration of MDMA at
moderate doses (Ricaurte et al., 1988a). Another study where
MDMA was administered at moderate doses reported signiﬁcant
decreases in the levels of 5-HIAA in the cerebrospinal ﬂuid (CSF),
and of both 5-HT and 5-HIAA in the cerebral cortex and striatum
(Insel et al., 1989). In addition, a study on the long-term effects of
exposure to MDMA in squirrel monkeys has revealed altered
patterns of 5-HT innervation in the brain that persisted for up to
7 years after drug discontinuation. Interestingly, the severity of the
changes involving 5-HT transmission appeared to be region-
dependent, as the decrease in 5-HT immunoreactivity only
appeared to be long-lasting in the hippocampal CA1 and CA2
ﬁelds, dentate gyrus, and subiculum (Hatzidimitriou et al., 1999).
Importantly, the route of administration seems to inﬂuence the
degree of 5-HT depletion induced by MDMA in non-human
primates, as oral administration has been reported to be less toxic
than subcutaneous injection (Ricaurte et al., 1988b). In this regard,
data have been obtained which show how repeated subcutaneous
administration of MDMA at a dose of 5 mg/kg produces a 86%
depletion of 5-HT in the frontal cortex, while the same dose of
MDMA elicits a 42% depletion of cortical 5-HT when repeatedly
administered orally (Ricaurte et al., 1988b). Furthermore, since it
has been calculated that a single 5 mg/kg oral dose administered to
non-human primates is equivalent to a 1.4 mg/kg dose adminis-
tered to a 70-kg human (McCann and Ricaurte, 2001), which
corresponds to a medium dose, these data may indicate a possible
risk of brain serotonergic nerve terminal injury in humans who
consume MDMA (Ricaurte et al., 1988b; McCann and Ricaurte,
2001).
Although several studies clearly demonstrate the neurotoxic
effects of MDMA in non-human primates, data on the behavioral
and cognitive effects of MDMA in these animals are scarce. Some
studies have suggested that no changes in a repeated acquisition
tasks (Frederick et al., 1998;Winsauer et al., 2002) or in a battery of
operant tasks (Frederick et al., 1995) occur in non-human primates
exposed to varying dosing regimens of MDMA. See Table 1 for
a summary of the protocols of the studies described above.
2.6. Studies in humans
The evaluation of the long-term effects of MDMA, including
neurotoxicity, in humans is complex, sinceMDMAusers frequently
consume it in the context of poly-drug abuse, together with other
psychoactive substances, such as ethanol, cannabis, and cocaine
(Schifano et al., 1998).
The use of amphetamine-related drugs in humans has been
linked to the emergence of deﬁcits in cognitive and executive
functions. However, in the case of MDMA users, it still remains to
be elucidated whether a relationship exists between these effects
and the possible serotonergic or dopaminergic toxicity induced by
the drug.
Single photon emission computed tomography (SPECT), posi-
tron emission tomography (PET), and functional magnetic reso-
nance imaging (fMRI) studies have generally found reductions in
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2010; Urban et al., 2012) as well as in abstinent subjects (Semple
et al., 1999; Reneman et al., 2001a,b). With regard to this, it is
interesting to mention that some evidence has been collected that
indicates SERT recovery in subcortical regions and neocortex after
prolonged MDMA abstinence (Buchert et al., 2006; Benningﬁeld
and Cowan, 2013) suggesting that at least some MDMA-induced
neurotoxicity could be reversible.
A SPECT study performed by Reneman and coworkers in a
cohort of MDMA-naı¨ve individuals, and in moderate, heavy, and
abstinent MDMA users, reported a dose-related decrease of SERT
levels in heavy MDMA users, while the SERT levels in abstinent
drug userswas similar to that detected inMDMA-naı¨ve individuals
(Reneman et al., 2001b,c). Interestingly, a reduction in SERT levels
was seen in heavy MDMA users of both genders, although it
reached statistical signiﬁcance in women, but not in men
(Reneman et al., 2001b). These results indicate that heavy use of
MDMA may be associated with toxic effects on serotonergic
neurons, and that women might be more susceptible to these
effects. Although these ﬁndingswould suggest that at least some of
the MDMA-induced effects on serotonergic system may be
reversible (Reneman et al., 2001c), a study in former MDMA
abusers has observed the presence of impairments in verbal
memory even at 1 year after drug discontinuation (Reneman et al.,
2001c). These latter data would suggest that, in contrast to the
effects on cortical serotonergic neurons, memory deﬁcits induced
by MDMA maybe long-lasting. In this regard, it is also noteworthy
that earlier ﬁndings demonstrated how MDMA users exhibit
signiﬁcant deﬁcits in a series of cognitive tasks and that these
behavioral deﬁcits are associated with decreased levels of 5-HIAA
in the CSF (McCann et al., 1999). In addition, recent studies have
observed that abstinent heavy MDMA users display hyperexcit-
ability (Bauernfeind et al., 2011) and chronic alterations in cortical
5-HT signaling compared with drug-naı¨ve individuals in both the
primary and secondary visual cortex (Di Iorio et al., 2012). The
hippocampus of heavy MDMA users might be particularly
vulnerable to the neurotoxic effects of MDMA (Gouzoulis-
Mayfrank et al., 2003; Daumann et al., 2005; Kish et al., 2010),
and functional alteration in this area evaluated by fMRI may
predict incipient cognitive decline several years before the
manifestation of a measurable cognitive failure. Interestingly,
Daumann and coworkers also found a heightened parietal
activation during working memory tasks after prolonged periods
of either continued use or abstinence fromMDMA (Daumann et al.,
2004). Based on these ﬁndings, it was suggested that altered
cortical activation might appear before the manifestation of
cognitive deﬁcits and may reﬂect the early stage of neuronal
injury induced by MDMA (Daumann et al., 2004).
Besides possibly promoting memory deﬁcits, the long-term
damage produced by MDMA has been suggested to be a potential
causal factor in psychiatric disorders, such as anxiety, phobia,
obsessive-compulsive behavior, and psychosis (Flaum and Schultz,
1996; Parrott et al., 2001). However, conﬂicting results have
been obtained in clinical investigations on this issue. It is
noteworthy that a recent PET study that compared 49 moderate
MDMA users with 50 non-users has reported a signiﬁcant
reduction in SERT binding throughout all cerebral cortices and
hippocampus (Kish et al., 2010), which are brain areas involved in
the regulation of mood. Moreover, the same cohort of MDMA
users, although not displaying overt behavioral abnormalities,
reported subnormalmood and exhibitedmodest, non-signiﬁcant,
deﬁcits in some tests of attention and memory, which might
potentially stem from the decrease in SERT binding sites (Kish
et al., 2010). Although the occurrence of psychotic disorders in
MDMA users has not been as thoroughly studied as METH-
associated psychosis, alterations in hippocampal activity couldpotentially contribute to the documented ability of MDMA to
induce psychotomimetic effects (Nifosi et al., 2009; Potash et al.,
2009; Patel et al., 2011).
While several studies have suggested thatMDMAmay harm the
serotonergic system in the human brain, it is less clear whether
MDMA may be toxic to human dopaminergic neurons. Over the
years, several clinical reports have found that patients diagnosed
with neurodegenerative diseases, such as PD, had a higher rate of
exposure to amphetamine-related drugs at a young age, compared
with the general population (Parrott et al., 2004; Callaghan et al.,
2010; Christine et al., 2010; Curtin et al., 2015). Since several
clinical studies recognize that PD has multiple origins, one
hypothesis is that amphetamine-related drugs may be part of
the wide array of factors leading to the dopaminergic neuron
degeneration that causes the disease (Obeso et al., 2010). In this
regard, it is noteworthy that MDMA has signiﬁcant afﬁnity for DAT
(Verrico et al., 2007) and promotes the release of DA in multiple
brain regions. Therefore, it is conceivable that prolonged exposure
to MDMA, similar to that proposed for other amphetamine-related
drugs (Garwood et al., 2006), may damage the dopaminergic
neurons in the human SNc. Hence, it is conceivable that these
damaged neurons could die earlier, therefore depleting the reserve
of neural cells necessary for normal neurological functions,
eventually ending up in the manifestation of PD (Garwood et al.,
2006; Todd et al., 2013).
2.7. Mechanisms of MDMA neurotoxicity
2.7.1. Biochemical mechanisms: oxidative stress and excitotoxicity
Metabolism of MDMA results in the formation of reactive
oxygen species (ROS), which ultimately induce long-term neuro-
toxic effects. Interestingly, several studies have reported that the
intracerebroventricular (ICV) administration of MDMA does not
induce neurotoxicity, even at dosesmuch higher than those having
neurotoxic effects when administered peripherally (Paris and
Cunningham, 1992; Esteban et al., 2001; Escobedo et al., 2005).
These latter ﬁndings indicate that MDMA has to be systemically
metabolized to produce its neurotoxic effects, and suggest that
MDMA metabolites are responsible for these effects, as suggested
by studies in cell cultures (see above). When MDMA is adminis-
tered at low doses to rats, it is chieﬂy N-demethylated to form 3,
4-methylenedioxyamphetamine (MDA) (Easton et al., 2003),
whereas in humans, O-demethylation to 3,4-dihydroxymetham-
phetamine (HHMA) predominates after MDMA administration,
irrespective of the dose (de la Torre et al., 2004). MDA is
metabolized to a-MeDA that can react either with glutathione
(GSH) to form 5-(GSH)-a-MeDA or with N-acetylcysteine (NAC) to
form 5-(NAC)-a-MeDA, and these compounds might be the main
metabolites responsible for the neurotoxic effects of MDMA
observed in rats. Miller and colleagues reported that acute ICV
administration of 5-(GSH)-a-MeDA and 5-(NAC)-a-MeDA to male
rats produced neurobehavioral changes similar to those observed
after systemic MDMA (Miller et al., 1996). In addition, 2,5-bis-
(GSH)-a-MeDA decreased the levels of 5-HT in the striatum,
hippocampus, and cortex 7 days after its ICV administration to
rats (Miller et al., 1997). Further support for the involvement of
metabolites in the neurotoxic effects of MDMA comes from
evidence that pretreatment of rats with acivicin, a g-glutamyl-
transpeptidase inhibitor, which increases the brain uptake of
5-(GSH)-a-MeDA, was associated with a more marked depletion
of 5-HT and 5-HIAA by MDMA in the striatum, hippocampus, and
cortex (Bai et al., 2001). Similar ﬁndings on the role of metabolites
in MDMA-mediated neurotoxicity have also been observed by in
vitro studies, where 5-(GSH)-a-MeDA, showed higher toxicity to
cultured cortical neurons than its parent compound, MDMA
(Capela et al., 2006a).
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tion of hydroxyl radicals in the mouse striatum (Go´rska et al.,
2014; Go´rska and Gołembiowska, 2014). ROS, together with
reactive nitrogen species (RNS), and the formation of neurotoxic
MDMA metabolites, may all contribute to neurotoxicity by
MDMA (Puerta et al., 2010; Green et al., 2003). Moreover, DA and
5-HT are metabolized by MAO-B, inducing the formation of
superoxide (O2
) and hydrogen peroxide (H2O2) (Capela et al.,
2009). This suggests that MAO-B is involved in the neurotoxic
effects of MDMA, a hypothesis which is further substantiated by
the ﬁnding that the MAO-B inhibitor selegiline prevents
serotonergic neurotoxicity in MDMA-treated rats (Sprague and
Nichols, 1995; Alves et al., 2007). Nitric oxide (NO) generated
from neuronal NO synthase (nNOS) also seems to be involved in
MDMA-induced neurotoxicity, as suggested by previous studies
that have demonstrated how nNOS inhibitors provide signiﬁcant
neuroprotection against long-term DA depletion in mice treated
with MDMA (Colado et al., 2001). Further support for the
involvement of oxidative stress in MDMA-induced neurotoxicity
comes from studies showing that this effect of MDMA is
ampliﬁed by either reduced levels or inactivation of antioxidant
enzymes, such as catalase, superoxide dismutase (SOD) and GSH
peroxidase (Cadet et al., 2001; Sanchez et al., 2003). In line with
this, MDMA produces a less marked oxidative stress and striatal
depletion of both DA and 5-HT in transgenic mice overexpressing
SOD than in wild-type mice (Jayanthi et al., 1999). Furthermore,
it is worth mentioning that treatment with antioxidant agents
has been found to afford neuroprotection in MDMA-treated rats.
In 1996, Gudelsky ﬁrst found that pretreatment with sodium
ascorbate and cysteine prevented the depletion of 5-HT observed
after MDMA administration in rats (Gudelsky, 1996). Similar
ﬁndings were obtained by subsequent studies that found
beneﬁcial effects of a-lipoic acid (Aguirre et al., 1999) and
ascorbic acid (Shankaran et al., 2001) on MDMA-induced
neurotoxicity.
Excitotoxicity includes a series of events, such as excessive
glutamate (GLU) release and activation of GLU receptors,
culminating in the increase in intracellular calcium levels,
generation of NO, and activation of apoptotic pathways, ultimately
resulting in cellular damage (Bruno et al., 1993; Yamamoto et al.,
2010). Importantly, glutamatergic dysfunction has been linked to
the manifestation of neurodegenerative disorders such as Alzhei-
mer’s disease and PD. This, together with the ability of amphet-
amine-related drugs to stimulate the release of GLU (Anneken
et al., 2013; Shoblock et al., 2003), suggests that this excitatory
amino acid could play a role in the neurodegenerative processes
induced by these drugs (Lipton and Rosenberg, 1994; Quinton and
Yamamoto, 2006).
However, limited evidence has been collected so far that
supports a role of GLU in MDMA-induced neurotoxicity. Earlier
studies have reported that blockade of the N-methyl-D-aspartate
(NMDA) GLU receptor produces hypothermia and attenuates
serotonergic nerve ending damage induced by MDMA in rats
(Finnegan et al., 1989; Farfel et al., 1992; Tao et al., 2014).
Moreover, studies by Colado and coworkers demonstrated that
NMDA receptor antagonists are neuroprotective against MDMA-
induced neurotoxicity only at doses that produce hypothermia,
and suggested that GLU is not crucial for MDMA-induced
neurotoxicity in both rats and mice (Colado et al., 1998, 2001).
In contrast, by performing in vitro studies with rat cortical
neurons, Capela and coworkers found that the NMDA receptor
antagonist MK-801 partially prevented the toxic effects of MDMA
in both normothermic and hyperthermic conditions (Capela et al.,
2006b). Taken together, these studies fail to provide clear
evidence of an involvement of GLU in the neurotoxic effects of
MDMA, and further studies on this issue appear warranted.2.7.2. Neuroinﬂammation
Another relevant issue related to MDMA-induced neurotoxicity
is that MDMA can trigger inﬂammatory processes in those brain
areas that exhibit dopaminergic and/or serotonergic terminal
degeneration, but not in brain areas where no modiﬁcations in
either DA or 5-HT levels occur (Yamamoto et al., 2010). Recent
studies have demonstrated that glial activation participates in the
events that induce neuronal damage, since chronic neuroinﬂam-
mation elevates the levels of glia-derived cytokines that exert
neurotoxic effects on vulnerable dopaminergic neurons (Barcia
et al., 2011). This mechanism provides support for a causal
relationship between MDMA-induced neurotoxicity and neuroin-
ﬂammation.
Several preclinical studies in rats and mice have demonstrated
thatMDMA elicits astroglial andmicroglial activation in themouse
striatum (Granado et al., 2008b; Costa et al., 2013; Frau et al.,
2013b), as well as in the cortex (Herndon et al., 2014; Costa et al.,
2014), and hippocampus (Costa et al., 2014; Lopez-Rodriguez et al.,
2014). Moreover, independent studies have shown that the toxic
and inﬂammatory effects of MDMA are exacerbated by its
concurrent administration with other psychoactive substances,
such as caffeine or ethanol (Hernandez-Rabaza et al., 2010;
Khairnar et al., 2010; Frau et al., 2013a) and, at the same time,
MDMA worsens neuroinﬂammation produced by toxins inducing
PD, such as MPTP (Costa et al., 2013).
2.7.3. Role of hyperthermia
The mechanism of MDMA-induced hyperthermia is complex,
and appears to not only involve serotonergic and dopaminergic
systems, but also adrenergic transmission (Sprague et al., 1998).
Moreover, MDMA-induced hyperthermia could depend, at least in
part, on the enhancement of ROS production and release of
cytokines, such as IL-1b, IL-6, and TNF (Green et al., 2004; Capela
et al., 2009). Finally, as mentioned above, manifestation of
hyperthermia in rats treated with MDMA is greatly inﬂuenced
by ambient temperature and housing conditions. MDMA adminis-
tration produces hypothermic response in rats housed at low
ambient temperature, while the drug can cause hyperthermic
responses in rats housed at high ambient temperature (Green et al.,
2005). This can be explained by considering that MDMA interferes
with heat-loss mechanisms, and consequently higher ambient
temperatures are more likely to impair the ability of the body to
dissipate the excessive heat.
Previous studies have demonstrated that several compounds
that elicit protective effects onMDMAneurotoxicity in rats, such as
MK-801 (Farfel et al., 1992), the 5-HT2A receptor antagonist
ketanserin, and the DA synthesis inhibitor a-methyl-p-tyrosine
(Malberg et al., 1996), are also able to lower body temperature.
Interestingly, studies of these compounds found that when the
core body temperature of rats was kept elevated, the neuropro-
tective effect was lost. Furthermore, pharmacological agents that
amplify the hyperthermic effects of MDMA, such as caffeine, have
been reported to potentiate MDMA-induced serotonergic deﬁcits
(McNamara et al., 2006). However, experiments with the 5-HT
reuptake blocker ﬂuoxetine have demonstrated that this drug can
provide protection against MDMA-induced neurotoxicity without
affecting the increase in body temperature (Capela et al., 2009).
Taken together, these ﬁndings indicate that while possibly playing
an important modulatory role, hyperthermia could not be an
essential factor in MDMA-induced neurotoxicity (Fig. 2).
2.7.4. Role of dopamine and of D1 and D2 dopamine receptors
As mentioned above, MDMA promotes the release of DA,
therefore, the possibility may exist that DA receptors play a role in
MDMA-mediated neurotoxicity (Capela et al., 2009; Bisagno and
Cadet, 2014). In this regard, it is noteworthy that previous studies
[(Fig._2)TD$FIG]
Fig. 2. Proposedmechanisms underlyingMDMA- andMETH-induced neurotoxicity.
The ﬁgure shows the potential interactions among the several factors, such as
hyperthermia, ROS and RNS, toxic metabolites, excitoxicity, neuroinﬂammation,
and high cortisol levels that may contribute to MDMA- and METH-induced
neurotoxicity. Reports in experimental animals indicate that high ambient
temperatures can inﬂuence the neurotoxic effect of MDMA and METH.
Moreover, MDMA and METH stimulate the release of DA and NA, while MDMA
may also promote the release of 5-HT. Catabolism of DA and 5-HT mediated by
MAO-B enzymes lead to the generation of reactive aldehyde species, and H2O2. This
latter species promotes formation of ROS, which contribute to MDMA and METH
neurotoxic effects. Both MDMA and METHmay stimulate the release of GLU, either
directly or indirectly via activation of serotonergic 5-HT2A receptors. By acting on
NMDA receptors, GLU activates NOS, leading to the overproduction of NO and
further stimulating the formation of damaging ROS. Neuroinﬂammation appears also
to play an important role in neurotoxicity by MDMA and METH, since both these
substances induce microglial activation that can lead to the production of many
reactive species (e.g., NO, O2
, cytokines) resulting in neurodegeneration. Finally,
both, MDMA and METH affect neuroendocrine functioning by stimulating the
activity of the HPA axis, and increasing the levels of cortisol that can also participate
in the neurotoxic effects of these drugs. " = elevation; + = potentiation of effect, as
observed by preclinical studies in experimental animals. * = the importance of this
mechanism has been clearly described for METH-mediated neurotoxicity only.
See the text for further details on each mechanism and its relevance.
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neuroprotective against neurotoxicity induced by amphetamine-
related drugs (Albers and Sonsalla, 1995). Granado and coworkers
(Granado et al., 2014) studied MDMA-induced neurotoxicity in DA
D1 or D4 receptor knock-outmice, and found that inactivation of D1
receptors attenuatedMDMA-induced hyperthermia and prevented
the striatal loss of DA and its metabolites, DOPAC and HVA
(Granado et al., 2014). In addition, D1 receptor knockout mice
showed a reduction in the expression of GFAP, amarker for reactive
astrogliosis (Aguirre et al., 1999; Adori et al., 2006) in the striatum
and a concomitant attenuation of dopaminergic terminal loss
induced by MDMA. With regard to D1 receptors, it is also worth
mentioning that activation of these receptors induces hyperther-
mia in mice (Zarrindast and Tabatabai, 1992). In contrast,
inactivation of D4 receptors was not able to counteract the
neurotoxic effects induced by MDMA.
Earlier evidence has demonstrated that the inactivation of D2
receptors decreases the DAT activity in the striatum (Dickinson
et al., 1999), and that D2 receptor knock-out mice are protected
from MDMA-induced hyperthermia, striatal DA loss, and gliosis
(Granado et al., 2011a). Antagonism or inactivation of D2 receptors
provides neuroprotection, possibly by either reducing the cytosolic
DA content through DAT inhibition or attenuating hyperthermia,
which is one of the mechanisms implicated in MDMA neurotoxici-
ty (Green et al., 2005; Capela et al., 2009).
Further support for a possible involvement of DA in the
neurotoxic effects of MDMA comes from pharmacological studies.
In 1988, Stone and coworkers proposed that endogenous DA is
important for the development of long-term MDMA-induced
neurotoxicity in rats (Stone et al., 1988). In line with an important
role of DA in MDMA neurotoxicity, bilateral lesions of thedopaminergic terminals with 6-hydroxydopamine (6-OHDA) were
reported to block MDMA-induced serotonergic neurotoxicity in
rats, while administration of the DA precursor 3,4-dihydroxy-L-
phenylalanine (L-DOPA) exacerbated this effect ofMDMA (Schmidt
et al., 1990). Later, in 1995, Yamamoto and colleagues demon-
strated thatMDMA indirectly elicits DA release by the activation of
5-HT2A receptors subsequent to the release of 5-HT in rats
(Yamamoto et al., 1995).
Furthermore, DAT inhibitors, such as GBR12909 and mazindol,
which prevent the increase in DA levels and ultimately the
generation of ROS, have been reported to attenuate serotonergic
toxicity by MDMA in rat (Stone et al., 1988). In addition, Benamar
and coworkers performed combined microdialysis and bioteleme-
try studies to determine the occurrence of parallel changes in the
extracellular levels of DA and body temperature after the
administration of MDMA (Benamar et al., 2008). They found that
the hyperthermic response produced by MDMA is accompanied
by an increase in the levels of DA in the preoptic anterior
hypothalamus, which was attenuated by the D1 antagonist SCH-
23390 (Benamar et al., 2008). Finally, it is interesting to observe
that previous studies indicate that, at low ambient temperature,
MDMA induces hypothermia (Gordon et al., 1991; Dafters and
Emily, 1998), which is mediated by stimulation of the D2 receptor
(Faunt and Crocker, 1987; Mechan et al., 2002). Conversely, at high
ambient temperature, MDMA induces hyperthermia, which stems
from the stimulation of D1 receptors (Mechan et al., 2002). Taken
together, these data indicate that both D1 and D2 DA receptors
could play an important role in MDMA-induced neurotoxicity.
3. Methamphetamine (METH)
3.1. History of METH
METH, a variant of amphetamine, was ﬁrst synthesized by
Nagayoshi Nagai in Japan in 1893 from the precursor chemical
ephedrine (Nagai and Kamiyama, 1988; Meredith et al., 2005).
METH use became prominent during World War II (1940s), when
various governments began giving their military personnel the
drug to ward off fatigue and enhance endurance and alertness
(Meredith et al., 2005; McGuinness, 2006). Amphetamine itself
was ﬁrst synthesized by Lazar Edeleanu, a Romanian chemist at the
University of Berlin in 1887. However, it was not used clinically
until 1920s, when Gordon Alles re-synthesized it for use in asthma,
hay fever and colds (Alles, 1993;Wolkoff, 1997; Sulzer et al., 2005).
In 1932 an amphetamine-based inhaler (Benzedrine) was mar-
keted for the treatment of nasal congestion (McGuinness, 2006),
and later amphetamines were promoted as treatments for various
ailments such as rhinitis and asthma (Derlet and Heischober, 1990;
Alles, 1993; Wolkoff, 1997; Sulzer et al., 2005; McGuinness, 2006).
The ﬁrst METH epidemic occurred in Japan where large
quantities of over-the-counter METH pills were available after
World War II (Wolkoff, 1997). The onset of epidemic in the USA
was slower due to prescription requirement. Nevertheless, the
prevalence of amphetamine use in the 1950s was high among
civilians including groups such as college students, truck drivers,
athletes, housewives, and individuals performing monotonous
jobs (Wolkoff, 1997; Donaldson and Goodchild, 2006). Although
amphetamine-based inhalers were banned by the Food and Drug
Administration (FDA) in late 1950s due to increases in their abuse
(Roll et al., 2006), amphetamine itself and some of its derivatives
were promoted as therapeutic agents for hyperactivity, obesity,
narcolepsy, and depression. Abuse of METH gained popularity in
the 1960s especially among individuals already using other illicit
drugs (Wolkoff, 1997). In the 1970s, the Controlled Substance Act
and classiﬁcation of amphetamines as Schedule II drugs (i.e., drugs
that have an acceptedmedical use but also have a high potential for
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of pharmaceutical amphetamines in the USA (Wolkoff, 1997).
However, despite these efforts, the use of METH increased in the
1980s, due in large part to production of the drug from the
precursor chemical ephedrine in clandestine labs (Cunningham
and Thielemeir, 1996). To counter this problem, the federal
government regulated the sale of pseudoephedrine commonly
used as cold medicine (Cunningham and Liu, 2003). Although this
act temporarily reduced METH-related problems (Cunningham
and Liu, 2003; Cunningham et al., 2008), the void in supplies was
ﬁlled by foreign producers (Cunningham et al., 2008; Cunningham
and Liu, 2008), where attempts to bring that production under
control have been problematic (NDIC, 2007). Nowadays, METH
abuse is a worldwide problem and concerted efforts by govern-
ments and enforcing agencies are conducted to combat this
epidemic ([8_TD$DIFF]UNODC, 2014). In the USA, street-names for METH
include crystal, crank, ice, glass, go, meth, speed, and zoom.
3.2. General toxicity of METH
At low therapeutic doses, METH can cause an elevated mood
and increase alertness, concentration, and energy in fatigued
individuals, while at higher doses it can induce psychosis,
rhabdomyolysis (a condition in which damaged skeletal muscle
tissue breaks down rapidly and may lead to kidney failure) and
cerebral hemorrhage.
The side effects of METH can include anorexia, hyperactivity,
dilated pupils, ﬂushed skin, excessive sweating, headache, irregu-
lar heartbeat, rapid breathing, high or low blood pressure, high
body temperature, diarrhea, constipation, blurred vision, dizziness,
twitching, numbness, tremors, dry skin, acne, pallor, dry mouth
and ‘‘meth mouth’’, a condition where the addicts may lose their
teeth abnormally quickly (Winslow et al., 2007; National
Geographic Channel, 2013; United States FDA, 2014). It is also
important to note that METH may cross the placental barrier or
may appear in breast milk, as a consequence of which exposed
infants can have a signiﬁcantly smaller head circumference and
birth weight, as well as manifest neonatal withdrawal symptoms
such as agitation, vomiting and tachypnea (Winslow et al., 2007;
Chomchai et al., 2010). METH may also lead to complex
psychological effects including euphoria, dysphoria, changes in
libido, insomnia or wakefulness, self-conﬁdence, sociability,
irritability, restlessness, grandiosity and repetitive and obsessive
behaviors as well as anxiety, depression, psychosis, suicide, and
violent behaviors (Westfall andWestfall, 2010; O’Connor, 2012[9_TD$DIFF]). At
extremely large overdose METH may produce symptoms such as
adrenergic storm, cardiogenic shock, brain bleed, circulatory
collapse, dangerously high body temperature, pulmonary hyper-
tension and kidney failure (Schep et al., 2010; Westfall and
Westfall, 2010; O’Connor, 2012; United States FDA, 2014). Death
from METH poisoning is preceded by convulsions and coma
(United States FDA, 2014). METH withdrawal is also associated
with a variety of conditions including anxiety, drug craving,
dysphoric mood, fatigue, increased appetite, increased or de-
creased movement, lack of motivation, sleeplessness or sleepiness,
and vivid or lucid dreams that may persist for 3–4 weeks (Shoptaw
et al., 2009). Curiously, the mental depression following METH
withdrawal is more severe and lasts longer than that of cocaine
(Winslow et al., 2007).
3.3. Neurotoxicity of METH: selectivity for the dopaminergic system
METH is directly neurotoxic to dopaminergic neurons and
hence its abuse may increase the risk of developing PD by 2 to 3-
fold (Callaghan et al., 2010, 2012; Curtin et al., 2015). METH can
also result in neurotoxicity to other neurons including serotonergic(Krasnova and Cadet, 2009; Silva et al., 2014), glutamatergic
(Simo˜es et al., 2007; Miyazaki et al., 2013; Zhang et al., 2014),
GABAergic (Zhang et al., 2006; Mizoguchi and Yamada, 2011; Shen
et al., 2013), as well as cholinergic neurons (Lim et al., 2014).
Serotonergic interactions ofMETHmay bemore related to itsmood
altering effects (Silva et al., 2014), glutamatergic interactions of
METHmay bemost relevant to its addictive, memory impairments
and psychotic-like effects related to glutamate receptors distribu-
tion (Simo˜es et al., 2007; Grant et al., 2012; Miyazaki et al., 2013;
Henley et al., 1989) whereas METH GABAergic interactions may be
most relevant to its cognitive dysfunctions and anxiety-like
symptoms observed during withdrawal (Mizoguchi and Yamada,
2011; Shen et al., 2013). Striatal cholinergic effects of METH are
believed to play a role in the motor impairments induced by the
drug (Lim et al., 2014). In addition, interactions of these
neurotransmitter systems with dopaminergic systems can also
inﬂuence the ﬁnal behavioral and neuronal effects of METH
(Miyazaki et al., 2013). However, in this review the primary focus
will be on METH interaction with the dopaminergic system and its
particular implications for PD.
3.4. In vitro studies: cell cultures
A number of studies have employed various dopaminergic cell
lines including the neuroblastoma-derived SH-SY5Y cells and
pheochromocyotoma-derived PC12 cells to investigate the mech-
anism of METH-induced neurotoxicity and evaluate novel neuro-
protectants. Thus, earlier experiments using PC12 cells showed
that METH signiﬁcantly increased formation of 3-nitrotyrosine
(3-NT), a biomarker of peroxynitrite, a reactive nitrogen species
(RNS), and cellular toxicity. In the same study, the authors reported
that pretreatment with antioxidants such as selenium and
melatonin could completely protect against the formation of 3-
NT Moreover, application of a selective neuronal nitric oxide
synthase (nNOS) inhibitor, 7-nitroindazole (7-NI), signiﬁcantly
protected against the formation of 3-NT (Imam et al., 2001), also, in
PD models (Solı´s et al., 2015). Parallel to these in vitro studies,
it was shown that METH caused striatal dopamine depletion and
that same agents were able to restore the dopamine level back
to normal, suggesting that peroxynitrite plays a major role in
METH-induced dopaminergic neurotoxicity and that selective
antioxidants and peroxynitrite decomposition catalysts can
protect against METH-induced neurotoxicity (Imam et al., 2001).
Later, using SH-SY5Y cells, it was shown that METH enhances
oxidative stress and aberrant mitochondrial biogenesis in these
cells and that vitamin E pretreatment can attenuate these effects
(Wu et al., 2007). Moreover, using the same cell lines, it was
observed that HIV protein, Tat, dramatically increases the toxicity
of METH (Cai and Cadet, 2008). See Table 2 for a summary of the
protocols of the studies described above.
More recently, it has been reported that melatonin can
attenuate METH-induced disturbances in mitochondrial dynamics
and degeneration in neuroblastoma SH-SY5Y cells (Parameyong
et al., 2013). Interestingly, caffeine inhibition of autophagy may
increaseMETH-induced toxicity in these cell lines (Pitaksalee et al.,
2015). Moreover, it was shown that acutely, METH may inhibit
voltage-gated Ca2+ [7_TD$DIFF] channels, but chronically upregulates L-type
channels, thus Ca2+ channel blockers may be of therapeutic
potential in METH-induced toxicity and dependence (Andres et al.,
2015).
3.5. In vivo studies in experimental animals
As mentioned above, METH is a neurotoxic drug that causes
deﬁcits and alterations in central dopaminergic pathways.
Repeated administration of METH in rodents has been shown to
Table 2
Experimental studies on neurotoxicity of METH.
Species Protocol of METH administration Reference
Primary microglial cell cultures 100mM for 24h Wang et al. (2014)
PC12 cells and SH-SY5Y cells 2.0–3.0mM for 24h Huang et al. (2015)
Mice 20mg/kg, s.c Sriram et al. (2006) and Kelly et al. (2012)
Mice 34mg/kg, i.p., at 2h intervals Thomas et al. (2010) and Angoa-Pe´rez et al. (2013)
Mice 35mg/kg or 310mg/kg, i.p, at 2–3h intervals Granado et al. (2010, 2011a,b), Ares-Santos et al. (2012, 2014),
Urrutia et al. (2014), and Carmena et al. (2015)
Mice 30 or 40mg/kg, single injection, i.p. Deng et al. (2007), Bowyer et al. (2008), Fantegrossi et al. (2008),
and Ares-Santos et al. (2014)
Rats Self-administer for 9h per day for 14 days
Self-administer for 3h per day for 14 days
Krasnova et al. (2014) and Mata et al. (2015)
Rats 410mg/kg, i.p, at 2h intervals Beauvais et al. (2011)
Rats 40mg/kg, single injection, s.c. or i.p. Cappon et al. (2000) and Jayanthi et al. (2005)
Monkeys Scaling-dose treatment for 4 weeks Jiang and Capitanio (2014)
Monkeys Scaling-dose treatment for 3 weeks Melega et al. (2008)
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striatum, reducing TH and DAT, accompanied by a reduction in TH
activity as well as reductions in the levels of DA, DOPAC and HVA,
and decreased levels of VMAT2. These effects occur primarily in the
striatum, but are also seen in the cortex, thalamus, hypothalamus,
and hippocampus (Ares-Santos et al., 2012; Granado et al., 2010,
2011a; Guilarte et al., 2003; Krasnova and Cadet, 2009; Ricaurte
et al., 1980). METH induces neurotoxicity in a dose-dependent
manner (Seiden and Sabol, 1996), as do other amphetamine-
derivatives like MDMA (Granado et al., 2008a,b). The loss of axonal
DA can be detected as early as 24 h after exposure to a relatively
high concentration of METH. Although some partial recovery of
striatal TH and DAT immunoreactivity may occur few days post-
treatment, the recovery is not complete and some of the losses
persist for long periods (Granado et al., 2011a,b; Ares-Santos et al.,
2012, 2014). Neurotoxic effects persist for more than seven days
and up to a month after METH exposure (Ares-Santos et al., 2012;
O’Callaghan and Miller, 1994; Granado et al., 2011b; Ares-Santos
et al., 2014). In addition, there is partial recovery of dopamine
levels in the striatum (Ares-Santos et al., 2012; Granado et al.,
2008a, 2011a), strongly suggesting that the regrown terminals are
functional. The mechanisms responsible for the partial recovery
are not known, but might involve compensatory sprouting and
branching as has been reported for regrowth following MPTP-
induced damage (Bezard et al., 2006). DA terminal recovery has
also been described in rhesus monkeys and velvet monkeys,
although in these species, it appears to occur on a slower timescale
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Fig. 3. The nigrostriatal pathway is more vulnerable than themesolimbic pathway toMET
putamen (CPu) and nucleus accumbens shell and core (AcbSh, AcbC) respectively of mthan in mice. METH-induced dopaminergic damage persists for
more than 12 weeks in velvet monkeys and more than 3 years in
rhesus monkeys (Melega et al., 1997; Seiden and Sabol, 1996),
demonstrating the persistence of METH-induced brain damage.
The persistent loss of DA axons in the striatum has been
correlated with DA cell body loss in the SNc, demonstrated by
rigorous stereological measurement of cell numbers with both TH
and Nissl staining. METH administration produces DA cell body
loss in the SNpc, as indicated by stereological counts in TH-stained
SN sections from treated mice (Granado et al., 2011b; Ares-Santos
et al., 2012). The observed pattern of TH-stained neuron loss is very
similar to the pattern of Nissl-stained neuron loss, indicating that
neuronal loss is speciﬁc to dopaminergic neurons. DA cell body loss
was conﬁrmed with Fluoro-Jade, a general marker of neuronal
degeneration that ﬂuoresces after administration of known
dopaminergic toxins such as 6-OHDA and MPTP (Schmued and
Bowyer, 1997). Dopaminergic cell loss is further supported by
measurements of the markers of apoptosis and neuronal death
(Sonsalla et al., 1996; Hirata and Cadet, 1997; Granado et al.,
2011a,b; Ares-Santos et al., 2012).
Interestingly, METH primarily affects the nigrostriatal pathway
and spares the mesolimbic dopaminergic pathway as TH levels in
the nucleus accumbens, the terminal ﬁeld of VTA, are not affected
by METH (Fig. 3) (Granado et al., 2010), paralleling the situation in
PD (Hurtig et al., 2000). It may be possible as well, that the strong
ﬁber loss produced at early times brought dendritic spine loss as
seen in PD models (Sua´rez et al., 2014). Furthermore, within theH-induced neurotoxicity. Photomicrographs of TH immunoreactivity in the caudate
ice treated with saline (Sal) or METH. Bar indicates: 500 mm.
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Fig. 4. Striosomes are more vulnerable than the matrix to neurotoxicity induced by
METH. TH-ir loss occurs predominantly in striosomes after METH treatment.
Striatal adjacent sections from amouse treatedwithMETHwere stained for TH orm
opioid receptor (MOR). Striatal weak TH patches corresponded with striosomes as
demonstrated by MOR-1 immunostaining. Bar indicates 500 mm.
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vulnerable to the damaging effects of METH (Fig. 4) (Granado et al.,
2010). Curiously, this pattern of degeneration is also observed
following administration of other neurotoxins such as MPTP,
MDMA, quinolinic acid and other NMDA receptor agonists, as well
as in other neurodegenerative diseases including early Hunting-
ton’s disease (Hedreen and Folstein, 1995) and ischemia/reperfu-
sion injury (Burke and Baimbridge, 1993). The differential
vulnerability of the striosomes may at least be partially due to
the low levels of superoxide dismutase (SOD), a known antioxidant
enzyme, in this area compared to the matrix (Medina et al., 1996).
In addition, it is now well recognized that stress can alter the
neurotoxic effects of various substances including those of METH.
Surprisingly though, an original study by Miller and O’Callaghan
reported that restraint stress actually protected against neurotoxic
effects of D-amphetamines (D-AMP) (Miller andO’Callaghan, 1996).
This effect of restraint stress, as suggested by the authors is likely
due to hypothermic actions of such a stressor, as adrenalectomy
also provided protection against D-AMP-induced striatal damage
(Miller and O’Callaghan, 1996). In general, however, stress is likely
to exacerbate the damaging effects of toxic substances via
activation of the HPA axis (Johnson et al., 2005). Indeed, recent
studies have veriﬁed the stimulating effects of METH on the HPA
axis and have provided evidence of neuronal c-Fos activation in
speciﬁc brain regions by METH (Tomita et al., 2013). Interestingly,
in the same study in mice it was demonstrated that HPA activation
by METH is correlated with METH-induced hyperthermia (Tomita
et al., 2013).
METH interactionwith theHPA axis is likely to contribute to the
psychological and psychiatric symptoms, particularly depression,
that is observed in adolescent and adult METH abusers (King et al.,
2010; Li et al., 2013). Thus, it is hypothesized that dysregulation of
the HPA axis reﬂected speciﬁcally in cortisol inability to suppress
ACTH secretion is a major contributor to METH-associated
psychiatric symptoms (Li et al., 2013). It would be of signiﬁcant
interest to further investigate the relationship between motor and
psychiatric effects of METH in both genders as adolescent females
appear to be more susceptible to the effects of METH than
adolescent males (King et al., 2010).
3.6. Studies in humans
METH has high popularity, attributed to its wide availability,
relative low cost and long duration of psychoactive effects. The
neurotoxic effects of METH in humans are similar to thoseobserved in experimental animals. Neuroimaging (PET) studies in
METH abusers have revealed reductions in striatal DAT levels that
are associatedwithmotor slowing andmemory impairment, this is
observed with brain PET studies in human abusers (Volkow et al.,
2001a). Other reports of neurotoxic effects of METH in human
abusers indicate poormotor performance associatedwith DAT loss
in the caudate nucleus and putamen (Volkow et al., 2001a,b;
McCann et al., 1998). Partial recovery of dopaminergic markers in
the striatum has also been reported in human METH-abusers after
periods of abstinence (Volkowet al., 2001a). Persistent DA terminal
losses have been documented after 11 months (Volkow et al.,
2001a) or 3 years of abstinence (McCann et al., 1998). Others
studies with magnetic resonance imaging (MRI) demonstrated
enlarged striatal volumes in METH abusers who recently
abstained, while greater cumulative METH use or longer duration,
was associated with smaller striatal structures (Chang et al., 2007).
There are evidences of neurodegenerative changes in SN of
METH abusers. For example, a speciﬁc decrease in pigmented
neurons in SN of human METH abusers, similar to that seen in PD
patients, has been reported (Bu¨ttner and Weis, 2006; Bu¨ttner,
2011). Moreover, the morphology of the SN (as measured by
transcranial sonography) in individuals with a history of stimulant
abuse, including METH, is abnormal, and is associated with
reduced DA uptake in the striatum and increased risk for
development of PD (Todd et al., 2013). It is therefore not
unreasonable to expect that METH consumers may be more
susceptible to neurodegenerative disorders such as PD (Granado
et al., 2013).
Recent epidemiological studies provided evidence that the risk
for developing PD is almost doubled in individuals with a history of
METH use (Callaghan et al., 2010). These results have been
reproduced using a larger and more age-diverse group of patients
(Callaghan et al., 2012), and another recent study suggests the risk
may be somewhat higher than previous estimates and indicates
differences in risk estimates between women and men (Curtin
et al., 2015). Use of METH has also been associated with impaired
executive and psychomotor function, as well as learning and
attention, underscored by alterations in basal ganglia and cortical
circuits (Paulus et al., 2002; Chang et al., 2007). Although motor
deﬁcits have been reported in chronicMETH abusers, these deﬁcits
do not typically involve gross movements, but rather affect ﬁne
motor dexterity, e.g. placing pegs in a pegboard (Caligiuri and
Buitenhuys, 2005; Rusyniak, 2011).
3.7. Mechanisms of METH neurotoxicity
3.7.1. Biochemical mechanisms: oxidative stress and excitotoxicity
The mechanisms responsible for the damage following METH
administration are complex and may involve various processes. In
this regard, oxidative stress is believed to be a prominent factor as
METH induces ROS such as hydroxyl radicals and superoxides that
lead to cellular toxicity (Cubells et al., 1994; Toborek et al., 2013).
METH, in addition to increasing DA release, impairs VMAT2
function, hence increasing cytosolic DA oxidation (Hansen et al.,
2002) and DA metabolism by MAO-B, producing DOPAC and
hydrogen peroxide (Cadet and Brannock, 1998; Olanow and
Tatton, 1999). Within the terminals, H2O2 reacts with transition
metal ions producing highly toxic hydroxyl radicals (OH) through
the Fenton reaction. Moreover, cytosolic DA can produce
superoxide anion (O2
) that in turn can also generate hydroxyl
radicals, leading to lipid peroxidation and activation of proteases
that ﬁnally trigger the cell death cascade. Anion superoxide reacts
with NO producing highly toxic peroxynitrites (ONOO) causing
cellular damage to proteins, nucleic acids and phospholipids by
overwhelming the antioxidative enzymes (Cadet and Brannock,
1998). ROS and RNS can also damage DNA structures causing loss
R. Moratalla et al. / Progress in Neurobiology 155 (2017) 149–170 161of genetic information leading to accelerated mitochondrial
dysfunction by inhibition of complex II electron transport chain.
This mitochondrial dysfunction, in particular, mediates the long-
term deﬁcits in markers of striatal dopaminergic terminals (Brown
and Yamamoto, 2003; Brown et al., 2005). The DA-induced
oxidative stress after METH is consistent with the selective
degeneration of DA terminals. Thus, reducing cytosolic DA with
alpha-methyl-para-tyrosine (a-MPT), that inhibits DA synthesis,
one can signiﬁcantly reduce METH-induced damage (Ares-Santos
et al., 2012; De Vito and Wagner, 1989; Fumagalli et al., 1998;
Granado et al., 2011a,b; Wagner et al., 1986). Conversely,
increasing cytosolic DA with L-DOPA, reserpine or in VMAT2
heterozygous mice, one can increase METH-induced damage
(Albers and Sonsalla, 1995; Ares-Santos et al., 2012; Fumagalli
et al., 1999; Granado et al., 2011a,b). Noteworthy, these oxidative
stress mechanisms induced by METH are also shared by other
amphetamine derivatives.
It is now well accepted that excess GLU, the most abundant
excitatory neurotransmitter in the brain, is responsible for
excitotoxic damage which is primarily mediated through increase
in Ca2+ inﬂux.METH has been shown to be a potent releaser of GLU,
resulting in activation of GLU receptors and eventual neuronal
damage (Yamamoto and Bankson, 2005). Indeed, blockade of
NMDA receptors, the major mediators of GLU excitotoxicity, by
selective antagonists (e.g. MK-801) can attenuate METH-induced
neurotoxicity in cell cultures (e.g. in PC12 cells) (Uemura et al.,
2003) as well as in various brain regions (Battaglia et al., 2002;
Bowyer et al., 2001; Chipana et al., 2008; Farfel et al., 1992; Fuller
et al., 1992; Golembiowska et al., 2003; Green et al., 1992; Ohmori
et al., 1993; Sonsalla et al., 1989, 1991; Weihmuller et al., 1992).
Interestingly chronic stress, suspected of enhancing METH-
induced toxicity is believed to be acting via further increase in GLU
concentrations and hence exacerbating damage to striatal DA
terminals (Quinton and Yamamoto, 2007; Tata and Yamamoto,
2008). This contention is supported by the ﬁndings that
corticosterone synthesis inhibitor (e.g.metyrapone), can attenuate
stress-induced enhanced GLU release and result in reduced METH
neurotoxicity (Tata and Yamamoto, 2008).
METH interaction with astrocytes may also contribute to its
excitotoxicity as astrocytes on their own exhibit a form of
excitability through increase in Ca2+ inﬂux. Thus, it is hypothesized
that activation of GLU receptors, coupled to various intracellular
signaling cascades, including activation of PKC, Akt, cAMP/PKA/
cAMP responsive element binding protein (CREB), and mitogen-
activated protein kinase (MAPK) and Janus kinase (JAK) pathways,
can lead to eventual METH-induced toxicity (Narita et al., 2006;
Cisneros and Ghorpade, 2012).
Over-expression ofa-synucleinmay also play an important role
in METH-induced death of dopaminergic neurons (Jiang et al.,
2014; Wang and Witt, 2014). Interestingly, oxidative stress, a
process implicated in neuronal toxicity may also result in
generation of a-synuclein oligomers (Norris et al., 2003). Alpha-
synuclein is a protein that is intimately involved in maintaining
the supply of synaptic vesicles in presynaptic terminals and may
also help regulate the release of DA (Ronzitti et al., 2014). Alpha-
synuclein is localized in the cytosol as well as in the inner
membrane of neuronal mitochondria where it may exert an
inhibitory effect on complex I activity of mitochondrial respiratory
chain, predisposing some neurons to degeneration (Liu et al., 2009;
Lam et al., 2011; Gaugler et al., 2012). Indeed, a-synuclein knock-
down in SH-SY5Y cells or in rats can protect againstMETH-induced
toxicity (Chen et al., 2013; Tai et al., 2014). It is also of interest to
note that S-nitrosylating protein disulphide isomerase may
mediate METH-induced a-synuclein aggregation and that inhibi-
tion of this enzyme may offer a therapeutic potential (Wu et al.,
2014). Recently a role for insulin-like growth factor binding protein5 in METH-induced apoptosis of dopaminergic neurons was
proposed (Qiao et al., 2014). In addition, altered energy metabo-
lism and inﬂammatory processes (see below) have also been
linked to METH-induced toxicity (Downey and Loftis, 2014).
3.7.2. Neuroinﬂammation
Microglial activation can occur rapidly after METH administra-
tion. Thus, METH can trigger the release of a number of pro-
inﬂammatory cytokines that can lead to glial dysfunction aswell as
neuronal death. Indeed, it has been shown that inhibition of
microglial activation by minocycline protects against the neuro-
toxic effects of amphetamine derivatives, including METH. METH
increases reactive microglia in the striatum, hippocampus, cortex,
and SN, peaking one day after administration. METH-induced
microglial activation was also recently observed in indusium
griseum, considered to be an extension of the hippocampus
(Carmena et al., 2015). Interestingly, microglial activation occurs
exclusively in DA-innervated areas (Ares-Santos et al., 2014).
METH also increases GFAP immunoreactivity in the striatum
(Ares-Santos et al., 2013) and in indusium griseum (Carmena et al.,
2015). Reactive gliosis is considered a universal reaction to injury
in the CNS and is used as a sensitive marker of neuronal damage.
Studies with other amphetamine-related drugs, such as MDMA,
and the neurotoxin 6-OHDA have found a similar pattern of
increase in GFAP (Ares-Santos et al., 2013). Of relevance is that
astrocytes, in contrast to microglia, can play a protective role by
increasing the levels of GSH, and facilitating sprouting. Thus,
providing growth factors, guidance molecules and scaffolding for
axonal regeneration (see Ares-Santos et al., 2013 for more detail).
Given that suppression of neuroinﬂammation mediated by
microglia activation may help prevent, or reverse, neurodegener-
ative diseases, a number of drugs have been tested over the years
that act on different parts of the inﬂammatory pathways. Some
drugs including nicotine, resveratrol, curcumin, and ketamine as
potential novel therapeutic agents in neurodegenerative diseases
have been suggested (Hurley and Tizabi, 2013).
3.7.3. Role of DA receptors: D1 receptors in METH-induced
neurotoxicity
The ﬁrst studies to implicate striatal D1-like receptors in the
neurotoxic effects of METH were pharmacological studies using
SCH-23390. This compound, an antagonist of D1-like receptors
(Bourne, 2001), also has agonist effects at 5-HT1C and 5-HT2C
receptors (Millan et al., 2001). When SCH-23390was administered
with METH, TH loss and METH-induced toxicity decreased
(Bronstein and Hong, 1995). Sonsalla et al. ﬁrst reported in
1986 that SCH-23390 effectively inhibited METH-induced depres-
sion of striatal TH activity in a dose-dependent manner and also
prevented the decrease in concentration of DA, DOPAC and HVA, in
this area (Sonsalla et al., 1986). These ﬁndings were conﬁrmed by
others showing prevention ofMETH-inducedDAdepletion by SCH-
23390 (O’Dell et al., 1993; Broening et al., 2005). Moreover, it was
further demonstrated that this compound also attenuated TH and
DAT depletion in the striatum (Metzger et al., 2000; Angulo et al.,
2004; Xu et al., 2005) and inhibited the increases in GFAP, caspases
3 and 8, and mediators of the calcineurin/NFAT/FasL-dependent
apoptotic cell death pathway (Jayanthi et al., 2005; Krasnova and
Cadet, 2009). However all these protective effects could be due to
the inespeciﬁc affects of SCH-23390 on 5-HT receptors as these
receptors have been shown to protect against MPTP intoxication
(Bezard et al., 2006). At the molecular level, D1-like receptors
blockade decreases DA-induced oxidation and cytotoxicity medi-
ated by the activation of extracellular-signal-regulated kinase
(ERK) and c-Jun N-terminal kinases (JNK) (Chen et al., 2004). In
addition, SCH-23390 completely blocked METH-induced expres-
sion of endoplasmic reticulum stress-related proteins (ATF3, ATF4,
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increase in pro-survival genes in response to endoplasmic
reticulum stress (including BIP/GRP-78 and P58IPK) and increased
expression of themitochondrial anti-apoptotic protein Bcl-2 in the
striatum (Beauvais et al., 2011). However, as SCH-23390 does not
distinguish between D1 and D5 receptors (Moratalla et al., 1996b)
and, as mentioned above, interacts with 5-HT receptors (Kvernmo
et al., 2006), it was not clear exactly which receptor subtypes were
involved in METH-induced neurotoxicity. A study in D1 receptor
knockout mice speciﬁcally implicated the D1 receptor in METH-
induced toxicity (Ares-Santos et al., 2012). Thus, D1 receptor
knockout mice were protected against reductions in striatal TH
and DAT expression (Fig. 5) and against loss of dopaminergic
neurons in the SNc followingMETH administration. In addition, D1
receptor knockout mice did not exhibit an increase in GFAP or in
macrophage-1 antigen (Mac-1) expression in these areas. Howev-
er, under these conditions, the D1 receptor knockout mice treated
with METH not only did not develop hyperthermia, but had a
hypothermic response instead (Ares-Santos et al., 2012). Other
studies with intrastriatal SCH-23390 injections supported the
results obtained with the D1 receptor knockout mice, implicating
hypothermia as an important mechanism in prevention of METH
toxicity in such cases (Friend and Keefe, 2013).
In summary, D1-like receptors involvement in METH-induced
toxicity is supported by the ﬁndings that inactivation of these
receptors provides neuroprotection against METH-induced toxic-
ity. Several mechanisms are postulated for this protection,
including blockade of the hyperthermic response, decreased DA
content and turnover and redistribution of DA inside the terminal.
Moreover, animals lacking D1 receptors can store more DA in
vesicles (Fig. 6). Because cytosolic DA levels determine the severity
ofMETH-induced toxicity (Guillot et al., 2008; Thomas et al., 2008),
the reduction in cytosolic DA in mice lacking D1 receptor is a
plausible mechanism for the decrease in METH-induced dopami-
nergic damage (Fig. 6) (Ares-Santos et al., 2012).
3.7.4. Role of DA receptors: D2 receptors in METH-induced
neurotoxicity
The ability of D2-like receptors antagonists to prevent the long-
term effects of METH has been evaluated by several groups.
[(Fig._5)TD$FIG]Fig. 5. Inactivation of D1 or D2 receptors protects against METH-induced decreases in TH
treatment with saline or METH, stained for TH. D1 and D2 receptors knockout mice wePharmacological agents that block D2-like receptors, can partially
or completely protect against METH-induced toxicity and can also
prevent the hyperthermic response (Albers and Sonsalla, 1995;
Eisch and Marshall, 1998; Metzger et al., 2000). Thus, sulpiride,
a D2-like receptor antagonist, dose-dependently blocked METH-
induced toxicity in mice, and eticlopride and raclopride (other D2-
like receptor antagonists) prevented METH-induced depletion of
the striatal DA content (O’Dell et al., 1993; Metzger et al., 2000).
These drugs also prevented reductions in DAT immunoreactivity
(Albers and Sonsalla, 1995; Xu et al., 2005) and DAT activity
following METH administration (Metzger et al., 2000). In addition,
eticlopride attenuated the decrease in VMAT2 caused by METH
treatment (Chu et al., 2010), while raclopride attenuated METH-
induced increases in GFAP in the striatum (Xu et al., 2005). Hence,
pharmacological studies using D2-like receptor antagonists indi-
cate a role for D2-like receptors in METH-induced apoptosis of
striatal neurons (Xu et al., 2005) and other METH-induced
toxicities. Moreover, unilateral striatal infusion of sulpiride
protects against DAT loss, implicating striatal D2-like receptors
in METH-induced neurotoxicity (Gross et al., 2011). However, D2-
like receptors antagonists are not speciﬁc for the D2 receptor
subtype as they may also block other D2-like receptors (e.g. D3 and
D4 receptors). Nevertheless, due to its presynaptic location and its
role in regulating DA release, the D2 receptor subtype appears to be
the most likely mediator of the neuroprotective effects of these
antagonists. Conﬁrmation of this contention was provided with D2
receptor knock-out animals. It was demonstrated that genetic
inactivation of D2 receptors prevents: METH-induced reductions in
striatal DA levels, ﬁber loss as seen with TH and DAT immunore-
activity as well as micro- and astrogliosis (Fig. 5). Moreover,
inactivation of D2 receptor prevented dopaminergic neuronal loss
in the SNc (Granado et al., 2011a). However, the absence of the D2
receptor also blocked the hyperthermic response to METH. Indeed,
D2 receptor knock-out mice exhibited a hypothermic response,
even at higher ambient temperature (29–30 8C) that is known to
potentiate METH-induced hyperthermic response (Granado et al.,
2011a). The inability to separate neuroprotective effects from
attenuation of hyperthermia after inactivation of D2 receptor does
not completely rule out a speciﬁc role for D2 receptor in METH-
induced neurotoxicity. Recent ﬁndings suggest that D2 receptorexpression in the striatum. Photomicrographs of striatal sections of mice 1 day after
re protected against TH loss induced by METH. Bar indicates 500 mm.
[(Fig._6)TD$FIG]
Fig. 6.Diagramof the different intracellular DA distribution in striatal dopaminergic terminals inWT, D1 andD2 receptor knockoutmice. D1 receptor knockoutmice (D1R/)
have lower DA levels thanWT animals. D1R/mice have higher vesicular DA and lower cytosolic DA thanWTmice, as demonstrated by fast scan cyclic voltammetry and by
HPLC (Ares-Santos et al., 2012). D2 receptor knockoutmice (D2R/) have lower vesicular and cytosolic DA and higher extracellular DA levels thanWTmice, as demonstrated
by fast scan cyclic voltammetry and by HPLC (Granado et al., 2011a,b). The reduced intracellular DA content in D2R/micemay be due to a lower DA re-uptake activity as a
consequence of decreased DAT function.
Source: Modiﬁed from Ares-Santos et al. (2014).
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other than an effect on body temperature. For example, reserpine,
which blocks hyperthermia, strongly potentiated METH-induced
neurotoxicity in wild-type mice indicating that hyperthermia is
not essential for neurotoxicity (Granado et al., 2011a). However, in
D2 receptor knock-out mice, not even pretreatment with reserpine
was able to abolish the neuroprotective effect of D2 receptor
inactivation against the toxicity caused by METH, strongly
suggesting that neuroprotection conferred by D2 receptor inacti-
vation is not completely dependent on its effect on body
temperature (Granado et al., 2011a). This contention is further
supported by the ﬁnding that the rectal temperatures were very
similar in reserpine-treated wild-type mice and in D2 receptor
knockout mice after METH injection, whereas the neurotoxic
effects clearly differed between these two experimental groups
(Granado et al., 2011a). Other plausible hyperthermia-indepen-
dent mechanisms underlying the neuroprotection observed after
D2 receptor inactivation are provided by the evidence that the
activity of striatal DAT, which is crucial for METH-induced
neurotoxicity (Fumagalli et al., 1998; Manning-Bog˘ et al., 2007;
Afonso-Oramas et al., 2009), is reduced in the absence of D2
receptor (Dickinson et al., 1999). Thus, it is proposed that the
decrease in DAT activity produced by inactivation of the D2
receptor blocks DA reuptake, resulting in lower intra-cytosolic DA
levels and hence, neuroprotection (Fig. 6) (Ares-Santos et al., 2013).
The above suggests that DA release and activation of DA D2
receptor are critical forMETH-induced neurotoxicity. Furthermore,
the neuroprotection against METH observed in the absence of the
D2 receptor might depend, at least in part, on inhibition of the
hyperthermic response produced by METH as well as a decrease in
vesicular DA levels.
Thus, inactivation of either the D1 or D2 receptor subtype may
provide protection against the neurotoxicity induced by METH,
albeit by slightly different mechanisms. Although the protection
provided by D1 or D2 receptor inactivation is due primarily to
decrease in cytosolic DA levels, themechanisms bywhich cytosolic
DA are lowered in D1 and D2 receptor knockout mice may differ
(Fig. 6). In D1 knockout mice, the decrease in cytosolic DA can be
mostly attributed to a high proportion of vesicular DA (Fig. 6)(Ares-Santos et al., 2012). In contrast, in D2 receptor knockout
mice, cytosolic DA is decreased by blocking DA reuptake and
decreasing DAT activity (Fig. 6) (Granado et al., 2011a). In addition,
blockade of hyperthermia is also likely to play a role in the
neuroprotection observed in both genotypes.
4. Conclusions and future directions
In summary, MDMA and METH are synthetic drugs whose
consumption started at the beginning of the twentieth century
with therapeutic purposes for their sympathomimetic properties,
but are now popular illegal recreational drugs in many countries
due to their psychostimulant effects. Their augmented popularity
is a cause of concern for health professionals and policy makers, as
MDMA andMETH users can become highly addicted to these drugs
and suffer undesirable consequences including increased risk of
developing PD. MDMA and METH effects are related to their
structural analogy to DA, and to their ability to release this
neurotransmitter. The mechanisms responsible for their neuro-
toxic actions are complex andmay involve inﬂammation, oxidative
stress, GLU, NO, hyperthermia, mitochondrial dysfunction, gliosis,
etc. The fact that DA receptors, in particular, D1 and D2 subtypes,
play an important role in initiation of the toxic effects of these
drugs, offers a window for therapeutic developments. Moreover,
because of observations that the neurotoxicity produced byMDMA
and METH is similar in humans and rodents, animal models and in
particular knockout mice represent extremely useful tools for
further elucidation of themolecularmechanisms of these toxicities.
New genetic technologies make it possible to identify new targets
that may lead to novel therapeutic strategies in prevention of the
devastating neurotoxic effects of MDMA and METH.
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